Q4 – 7: Product Collection

*Multiple Collections versus Multiple Products
This form collects information for a single product. PBSC collected from a single mobilization event (a mobilization event is the planned administration of growth factors or systemic therapy designed to enhance stem cell collection), even when collected over several days, is considered one product.
Multiple products are collected when, for example, the donor requires another mobilization to collect a product at a later date. The collection from the second mobilization event is considered a different product and should be reported on an additional Hematopoietic Cellular Transplant (HCT) (2006).

Question 4: Date of first collection for this mobilization

Report the first date the cell collection was performed. If a collection event occurs over multiple days, report the date the collection started (i.e., Day 1).

• Example 1: An autologous recipient was mobilized with G-CSF and underwent a two-day PBSC collection. Since the collection and mobilization methods remained the same over the duration of the collection, this collection is considered one product. Report the collection start date as the date of product collection.
• Example 2: An autologous recipient was mobilized with G-CSF and underwent a two-day PBSC collection. The collected cell counts were poor, and no further collections were attempted. One week later the donor was re-mobilized with G-CSF and a second PBSC collection was performed. Due to the recipient having two mobilization events, these are considered as two separate products, and two Hematopoietic Cellular Transplant (HCT) (2006) forms should be submitted. The date of product collection should be the first day of collection of the mobilization event for which the form is being completed.

This question is only enabled for PBSC and bone marrow products from non-NMDP donors.

Question 5: Were anticoagulants or other agents added to the product between collection and infusion?

This question is intended to capture anticoagulants added to the product between collection and prior to infusion. Anticoagulants are often added to PBSC products and are typically documented on the product bag label.

Indicate if anticoagulants or other agents were added to the product between collection and infusion.

If anticoagulants were given directly to the donor before or during cell collection and not added to the stem cell product itself, report No.

This question is only enabled for PBSC and bone marrow products from non-NMDP donors.

Questions 6 – 7: Specify anticoagulant(s) (check all that apply)

Select all anticoagulants added to the reported product. Check all that apply.

• Acid citrate dextrose (ACD, ACD-A)
• Citrate phosphate dextrose (CPD, CPD-A)
• Dimethylsulfoxide (DMSO)
• Ethylenediaminetetraacetic acid (EDTA)
• Heparin
• Plasmalyte
  

If an anticoagulant added to the product is not listed on the form, check Other agent, and specify the anticoagulant’s name.

Section Updates:

Question Number	Date of Change	Add/Remove/Modify	Description	Reasoning (If applicable)
.	.	.	.	.

Copyright © 2004-2025 The Medical College of Wisconsin, Inc. and NMDP. All Rights Reserved.
CIBMTR® (Center for International Blood and Marrow Transplant Research) is a research collaboration between the Medical College of Wisconsin and NMDP.